Evidence map›Paper›PMID 35779228›Full record

ArticleMolecular and cellular biochemistry2023

SOX9 is a target of miR-134-3p and miR-224-3p in breast cancer cell lines.

Tsu-Yang Chao, Theresa Kordaß, Wolfram Osen, Stefan B Eichmüller

Open access · hybridAbstract read
In one paragraph

Article in Molecular and cellular biochemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. CDK1 drives SOX9-mediated chemotherapeutic resistance in gastric cancer.Journal of experimental & clinical cancer research : CR · 2025
    Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Tsu-Yang Chao *GMP & T Cell Therapy Unit, German Cancer Research Center (DKFZ), 210, Im Neuenheimer Feld 280, D-69120, Heidelberg, Germany.
Theresa Kordaß *GMP & T Cell Therapy Unit, German Cancer Research Center (DKFZ), 210, Im Neuenheimer Feld 280, D-69120, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-1222-8518
Wolfram OsenGMP & T Cell Therapy Unit, German Cancer Research Center (DKFZ), 210, Im Neuenheimer Feld 280, D-69120, Heidelberg, Germany.
Stefan B EichmüllerGMP & T Cell Therapy Unit, German Cancer Research Center (DKFZ), 210, Im Neuenheimer Feld 280, D-69120, Heidelberg, Germany. s.eichmueller@dkfz.de.
German Cancer Research Center · DE

Funding

Dr. Mildred Scheel Stiftung für Krebsforschung 70113862
6 · The paper itself

Abstract

The transcription factor SOX9 represents an important mediator of breast cancer progression. miRNAs are small non-coding RNAs inhibiting translation of target genes upon interaction with the 3'-UTR region of respective mRNA molecules. Deregulated miRNA expression is involved in hallmarks of cancer like sustained proliferation and inhibition of apoptosis. Here, we investigated the miRNA-mediated regulation of SOX9 expression in two breast cancer cell lines, thereby providing further insights into cellular mechanisms driving breast cancer progression. The modulating effects of miR-134-3p, miR-224-3p, and miR-6859-3p on SOX9 expression were analyzed by qPCR and Western blot in human MDA-MB-231 breast cancer cells. Direct binding of the above-mentioned miRNAs to the SOX9 3'-UTR was assessed by luciferase reporter assays and site-directed mutagenesis. Expression levels of the investigated miRNAs in tumor samples versus healthy tissues were analyzed in silico using publicly available databases. Transfection of miR-134-3p, miR-224-3p, or miR-6859-3p reduced SOX9 expression on mRNA and protein level. Reporter assays proved direct binding of miR-134-3p and miR-224-3p to the SOX9 3'-UTR in MDA-MB-231 and MCF-7 cells. Expression analysis performed in silico revealed reduced expression of both miRNAs in breast cancer tissues. We describe three novel miRNAs targeting SOX9 in human breast cancer cell lines. Among them miR-134-2p and miR-224-3p might act as tumor suppressors, whose down-regulation induces elevated SOX9 levels thereby promoting breast cancer progression.

Indexed as

Breast NeoplasmsMicroRNAs3' Untranslated RegionsCell Line, TumorCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMCF-7 CellsSOX9 Transcription Factor3' Untranslated RegionsMicroRNAsMIRN134 microRNA, humanMIRN224 microRNA, humanSOX9 protein, humanSOX9 Transcription FactorBreast cancermiRNAsSOX9

Identifiers

PMID35779228
PMCPMC9886654
OpenAlexW4283775343

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.